Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1’087’000.00 KRW | +3.23% | +8.70% | +14.54% |
23.01. | Samsung Biologics' Q4 Net Attributable Income springt um 11%, Aktien steigen um 4% | MT |
17.01. | Samsung Biologics betritt mit neuer Einrichtung den Markt für Antikörper-Wirkstoff-Konjugate | MT |
Zu einer Liste hinzufügen 0 ausgewählt | Umsatz | Nettogewinn | EBIT-Marge | ROE | ROA | Verschuldungsgrad | |
---|---|---|---|---|---|---|---|
2.85 Mrd. | 23,21% | 30,14% | 9.12x | 5.26x | -0.16x | ||
14.8 Mrd. | 17,85% | 25,76% | 15.94x | 7.12x | 2.22x | ||
5.81 Mrd. | 6,53% | 12,51% | 8.83x | 5.07x | 1.61x | ||
9.84 Mrd. | 11,80% | 25,87% | 15.21x | 4.52x | 1.94x | ||
3.7 Mrd. | 16,17% | 16,79% | 12.5x | 9.47x | -5.2x | ||
464 Mio. | 30,08% | 34,32% | -22.39x | -18.84x | 3.15x | ||
74.43 Mio. | 3,49% | 10,09% | -2.44x | -1.34x | 13.25x | ||
777 Mio. | 22,64% | 25,43% | 9.97x | 7.81x | -2.15x | ||
2.42 Mrd. | 6,93% | 6,54% | 3.51x | 2.54x | 0.05x | ||
2.2 Mrd. | 10,89% | 20,27% | 7.98x | 3.81x | 2.51x | ||
7.46 Mrd. | 15,25% | 17,71% | 29.09x | 18.29x | -0.34x | ||
9.3 Mio. | 6.913,92% | 6.528,75% | - | -108.65x | -2.18x | ||
875 Mio. | 16,56% | 27,06% | -8.84x | -5.38x | 10.88x | ||
1.12 Mrd. | 22,34% | 27,94% | 6.06x | 5.7x | - | ||
7.29 Mrd. | 0,90% | 15,52% | 3.72x | 1.04x | 6.42x | ||
731 Mio. | 21,42% | 34,84% | 11.93x | 8.19x | - | ||
271 Mio. | 88,41% | 85,67% | -159.21x | - | 0.93x | ||
296 Mio. | 26,45% | 32,41% | 33.98x | - | - | ||
753 Mio. | 27,74% | 39,28% | 13.7x | 9.61x | 0x | ||
258 Mio. | 10,94% | 8,38% | - | - | - | ||
Durchschnitt | 3.1 Mrd. | percentage-no-prefix | percentage-no-prefix | -0.63x | -2.69x | 2.06x | |
Gewichteter Durchschnitt nach Marktkapitalisierung | 6.27 Mrd. | percentage-no-prefix | percentage-no-prefix | 7.16x | 2.07x | 1.70x |
- Börse
- Aktien
- A207940 Aktie
- Sektor Samsung Biologics Co.,Ltd.
- Finanzielle Vergleiche
MarketScreener is also available in this country: United States.
Switch edition